Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission

By Larsen Thomas Stauffer   Møller Michael Boe   de Stricker Karin   Nørgaard Peter   Samuelsson Jan   Marcher Claus   Andersen Morten T.   Bjerrum Ole Weis   Hasselbalch Hans Carl  

Hematology, Vol. 14, Iss. 6, 2009-12 ,pp. : 331-334

Maney Publishing

Access to resources Recommend Favorite

Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F

By Steimle C.   Lehmann U.   Temerinac S.   Goerttler Ph.   Kreipe H.   Meinhardt G.   Heimpel H.   Pahl H.  

Annals of Hematology, Vol. 86, Iss. 4, 2007-04 ,pp. : 239-244

Springer Publishing Company

Access to resources Recommend Favorite

Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis

By Silver Richard T   Kiladjian Jean-Jacques   Hasselbalch Hans Carl  

Expert Review of Hematology, Vol. 6, Iss. 1, 2013-02 ,pp. : 49-58

Informa Healthcare

Access to resources Recommend Favorite

Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature

By Hauswirth A.W.   Simonitsch-Klupp I.   Uffmann M.   Koller E.   Sperr W.R.   Lechner K.   Valent P.  

Leukemia Research, Vol. 28, Iss. 3, 2004-03 ,pp. : 249-257

Elsevier

Access to resources Recommend Favorite

Outcome of kidney transplant in chronic hepatitis C virus patients: effect of pretransplantation Interferon-Alpha 2b monotherapy

By Gonzalez-Roncero F.   Gentil M.A.   Valdivia M.A.   Algarra G.   Pereira P.   Toro J.   Sayago M.   Mateos J.  

Transplantation Proceedings, Vol. 35, Iss. 5, 2003-08 ,pp. : 1745-1747

Elsevier

Access to resources Recommend Favorite